July 2021 - Zahrawi

We are honored to announce that Elekta Solutions AB has appointed Zahrawi Group as their new official Sales Partner for their Brachytherapy products line in the Gulf and KSA starting from June 2021.

Elekta is a leader in precision radiation medicine. The company’s success is based on innovations that helps improving the standards of healthcare worldwide. They offer more precise, personalized radiotherapy treatments and their solutions for cancer care and brain disorders are tailored to target the tumor and protect the patient.

Their Brachytherapy solutions are designed for precise, targeted treatment of various cancers such as cervical, prostate, breast, skin and rectal. Brachytherapy is suited as a single modality or in combination with other treatments such as external beam radiation therapy. Elekta Brachytherapy offers you the best-in-class clinical solutions, a worldwide presence and above all, a commitment to patient care. Elekta Brachytherapy solutions include Esteya® electronic brachytherapy, Flexitron® afterloader, Oncentra® Brachy treatment planning, the broadest range of applicators in the industry and Real-time Prostate Solutions.

Zahrawi Group Radiotherapy team is so excited to collaborate with a prestigious company as Elekta. As expressed by Abdulrahman Ramadan, Zahrawi Vice President “We truly believe our customers will greatly benefit from this partnership as both Zahrawi and Elekta models align beautifully with a focus on providing the best Healthcare solutions to our clients”.

We are proud to announce that thanks to the hard work of our Intervention Cardiology team in Saudi Arabia, the first DynamX implant case was successfully performed in KSA this 5th June 2021 at Al Mana General Hospital in Dammam.

It is the first time in Saudi Arabia that we use such an innovative system to treat coronary artery diseases. The DynamX™ Drug Eluting Coronary Bioadaptor System from our principal company Elixir is the first coronary artery implant designed to adapt to vessel physiology and the Doctor who operated gave a very good initial feedback on its performance.

The DynamX System initially functions like a traditional drug-eluting stent (DES) with similar deliverability and radial strength while the vessel heals. Over six months the polymer is resorbed, releasing the uncaging elements to safely allow for positive adaptive remodelling and restoration of vessel function.

Congratulations to Ahmad Hoblos and the Intervention Cardiology team for this achievement.